Natera And 2 Other Companies That May Be Trading Below Their Estimated Value

The United States market has experienced a notable upswing, climbing 1.6% in the last week and rising 28% over the past year, with earnings expected to grow by 17% annually. In such an environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on undervalued assets.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

Name Current Price Fair Value (Est) Discount (Est) Robert Half (RHI) $29.44 $58.73 49.9% Rayonier (RYN) $20.89 $40.26 48.1% Merck (MRK) $118.72 $228.62 48.1% Live Oak Bancshares (LOB) $38.03 $74.21 48.8% Goosehead Insurance (GSHD) $34.39 $66.13 48% Gilead Sciences (GILD) $134.43 $266.16 49.5% FB Financial (FBK) $52.69 $101.61 48.1% CoStar Group (CSGP) $32.20 $61.96 48% Capstone Energy+ (CGEH) $13.55 $26.05 48% Bowhead Specialty Holdings (BOW) $26.62 $52.60 49.4%

Click here to see the full list of 137 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Here we highlight a subset of our preferred stocks from the screener.

Natera

Overview: Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally, with a market cap of approximately $31.99 billion.

Operations: The company generates revenue of $2.50 billion from its molecular testing services worldwide.

Estimated Discount To Fair Value: 26.2%

Natera is trading at $223.37, significantly below its estimated future cash flow value of $302.72, suggesting it may be undervalued based on discounted cash flows. Despite a forecasted slower revenue growth rate of 14.8% annually, the company is expected to become profitable within three years, with earnings projected to grow substantially each year. However, recent insider selling and low return on equity forecasts could be potential concerns for investors evaluating its long-term prospects.

Upon reviewing our latest growth report, Natera's projected financial performance appears quite optimistic. Click to explore a detailed breakdown of our findings in Natera's balance sheet health report.NTRA Discounted Cash Flow as at Jun 2026

Seagate Technology Holdings

Overview: Seagate Technology Holdings plc provides data storage technology and infrastructure solutions across various regions, including Singapore, the United States, and the Netherlands, with a market cap of $199.06 billion.

Operations: The company generates revenue primarily from the manufacture and distribution of storage solutions, amounting to $11.01 billion.

Estimated Discount To Fair Value: 32%

Seagate Technology Holdings is trading at $879.8, below its estimated future cash flow value of $1,293.75, highlighting potential undervaluation based on cash flows. Earnings have grown significantly and are expected to continue outpacing the US market with a forecasted annual growth of 37.3%. Despite high debt levels and recent insider selling, Seagate's revenue growth prospects remain robust at 23.1% annually, supported by innovative storage solutions like the Mozaic platform and strategic share buybacks totaling $5.41 billion since 2018.

Story Continues

According our earnings growth report, there's an indication that Seagate Technology Holdings might be ready to expand. Navigate through the intricacies of Seagate Technology Holdings with our comprehensive financial health report here.STX Discounted Cash Flow as at Jun 2026

AbbVie

Overview: AbbVie Inc. is a research-based biopharmaceutical company involved in the research, development, manufacturing, commercialization, and sale of medicines and therapies globally, with a market cap of approximately $384.67 billion.

Operations: AbbVie's revenue primarily comes from its Innovative Medicines and Therapies segment, which generated $62.82 billion.

Estimated Discount To Fair Value: 47.8%

AbbVie is trading at US$217.72, significantly below its estimated future cash flow value of US$417.04, indicating potential undervaluation based on discounted cash flow analysis. Despite a high debt level and significant insider selling recently, AbbVie's earnings are expected to grow substantially at 25.2% annually, outpacing the broader U.S. market's growth rate. Recent regulatory approvals in the EU for VENCLYXTO combinations expand treatment options for chronic lymphocytic leukemia, enhancing AbbVie's therapeutic portfolio and potential revenue streams.

In light of our recent growth report, it seems possible that AbbVie's financial performance will exceed current levels. Click here and access our complete balance sheet health report to understand the dynamics of AbbVie.ABBV Discounted Cash Flow as at Jun 2026

Taking Advantage

Explore the 137 names from our Undervalued US Stocks Based On Cash Flows screener here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NTRASTX and ABBV.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments